ClinicalTrials.gg
RecruitingNCT07001709ENABLEUpdated Jun 3, 2025

Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)

A Phase 4 interventional study of Oxycodone oral capsule 15 mg and Abiraterone Acetate Tablets 500 mg in Prostate Cancer and Pain Cancer, sponsored by Deventer Ziekenhuis. Recruiting at 1 site in Netherlands. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by Deventer Ziekenhuis · Phase 4, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 1 year after the study started (first participant enrolled Apr 2024, registered Apr 2025).
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.

Planned enrollment
73rd of 98
29 · median 56
Started
2024
with 2 others
Phase 4
4 of 98
1 open now
Primary completion
2025-12
later than 8 of 28 live
Registered
97th of 98
by date

Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 73rd largest by planned enrollment, is one of 3 that started in 2024, is one of 4 in phase 4, reaches primary completion later than 8 of the 28 other live ones, and was the 97th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Abiraterone Acetate

Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Prostate cancer often leads to bone metastases, which require adequate pain management with opioids such as oxycodone. This study investigates whether abiraterone - a drug used in the treatment of prostate cancer - affects the pharmacokinetics of oxycodone in order to improve pain management.

Read the detailed description

Rationale: Oxycodone is an opioid receptor agonist metabolized primarily by CYP3A4, and to a lesser extent by CYP2D6. Abiraterone is an androgen biosynthesis inhibitor prescribed to men with castration resistant prostate cancer (CRPC). The ENABLE study is a follow-up to the ENZYME study in which it was described that enzalutamide increases oxycodone metabolism in patients with CRPC. It is expected that concomitant use of abiraterone has no clinically relevant effect on oxycodone's plasma concentration since it solely inhibits CYP2D6. Therefore, discontinuing abiraterone treatment is not expected to result in toxicity. This might positively affect pain management and pharmacovigilance in patients with CRPC.

Objective: To investigate the effect of abiraterone on the pharmacokinetics (PK) of oxycodone following a single dose of 15 mg normal-release oxycodone in men with prostate cancer.

Trial design: A prospective, open-label, two-arm parallel clinical study.

Subjects will visit the hospital once for approximately nine hours. After screening for hypercapnia, subjects will receive one oral dose of 15 mg (10 mg and 5 mg capsules) normal-release oxycodone. In total, nine blood samples will be collected during the day for the control group and ten blood samples for the abiraterone group. Seven blood samples will be collected at predetermined times (t= 0.5, 1, 1.5, 2, 3, 5, 8 hours) in order to analyze the metabolism of oxycodone. One blood sample will be collected to determine abiraterone serum trough concentrations (abiraterone arm). In addition, two blood samples will be collected for patient characteristics, including one sample for genotyping of CYP3A4 and CYP2D6.

03

Conditions studied

  • Prostate Cancer
  • Pain Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed prostate cancer;
  • Males aged 18 years or older;
  • Treated with abiraterone 1000 mg once daily for at least 10 days (abiraterone arm).
  • Not treated with abiraterone 1000 mg once daily for at least 10 days (control arm).

Exclusion criteria

Exclusion Criteria:

  • Use of oxycodone short acting \<48 hours, or long acting \<96 hours prior to the study day;
  • Use of other opioids in the 14 days prior to the study day (see also appendix A);
  • Use of other medication that has pharmacokinetic or pharmacodynamics interactions with oxycodone (see also appendix A);
  • Arm 1: dose reduction or successive days of treatment interruption within 10 days prior to the study day (arm 1);
  • Arm 2: treatment with abiraterone within 10 days prior to the study day;
  • A (BMI) outside the range of 18 - 30 kg/m2;
  • If hypersensitive to oxycodone;
  • patients suffering from diarrhea
  • If any type of abnormality; active or symptomatic viral hepatitis or chronic liver disease (e.g. classification with B, Child-Pugh C);
  • Known in the liver that would affect drug metabolism;
  • Patients with a or CYP2D6 polymorphism;
  • Moderate-severe renal dysfunction ( \<60 ml/min/1.73m2) that affects drug metabolism ;
  • Subjects with significant respiratory depression resulting in the need of oxygen therapy or objective hypoventilation (respiratory rate \<12/min);
  • Hypercapnia (venous pCO2 outside the range of 5.5 - 6.7; pH outside the range 7.30 - 7.40);
  • Subjects with, a history of bronchial asthma, or pulmonary heart disease;
  • Subjects who started their first cycle of chemotherapy during the 2 weeks before the study day;
  • Major surgery within 1 month prior to screening or planned surgery;
  • A history of drug abuse
  • Patients receiving opioid substitution therapy for opioid addiction (e.g. methadone or buprenorphine) and/or suffering from opioid withdrawal
  • Patients with evidence of gastrointestinal disease;
  • Patients who are for blood sampling;
  • Unable to swallow solid, oral dosage forms whole with water;
  • Participation in a clinical trial study at the time of enrolment or within 30 days or 5 half-lives of enrolment, whichever is longer;
  • Previous gastric bypass or gastric band surgery.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (estimated)

Study arms

  • Other
    Control group

    Receive 15 mg oxycodone (direct release) without the use of abiraterone. The plasma concentration of oxycodone, noroxycodone, oxymorphone and noroxymorphone is measured. In addition, one blood sample is drawn for determine patient characteristics and genotyping of CYP3A4 and CYP2D6 is determined.

    Drug: Oxycodone oral capsule 15 mg

  • Other
    Abiraterone group

    Receive 15 mg oxycodone (direct release) and abiraterone. The plasma concentration of oxycodone, noroxycodone, oxymorphone and noroxymorphone is measured. In addition, one blood sample is drawn for determine patient characteristics, the serum through concentration of abiraterone and genotyping of CYP3A4 and CYP2D6 are determined.

    Drug: Oxycodone oral capsule 15 mg · Drug: Abiraterone Acetate Tablets 500 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax Oxycodone

    Maximum measured concentration of oxycodone

    Time frame: Measured at one of the time points (t= 0.5, 1, 1.5, 2, 3, 5, 8 hours)

  2. T1/2 oxycodone

    Measured half-life of oxycodone

    Time frame: t= 0.5, 1, 1.5, 2, 3, 5, 8 hours

  3. AUC0-8h oxycodone

    Area under the curve of oxycodone from 0 to 8 hours after ingestion of oxycodone.

    Time frame: From 0 to 8 hours after ingestion of oxycodone

Secondary outcomes

  1. Cmax noroxycodone

    Maximum measured concentration of noroxycodone

    Time frame: Measured at one of the time points (t= 0.5, 1, 1.5, 2, 3, 5, 8 hours)

  2. AUC0-8h noroxycodone

    Area under the curve of noroxycodone from 0 to 8 hours after ingestion of oxycodone.

    Time frame: From 0 to 8 hours after ingestion of oxycodone

  3. Cmax oxymorphone

    Maximum measured concentration of oxymorphone

    Time frame: Measured at one of the time points (t= 0.5, 1, 1.5, 2, 3, 5, 8 hours)

  4. AUC0-8h oxymorphone

    Area under the curve of oxymorphone from 0 to 8 hours after ingestion of oxycodone.

    Time frame: From 0 to 8 hours after ingestion of oxycodone

  5. Cmax noroxymorphone

    Maximum measured concentration of noroxymorphone

    Time frame: Measured at one of the time points (t= 0.5, 1, 1.5, 2, 3, 5, 8 hours)

  6. AUC0-8h noroxymorphone

    Area under the curve of noroxycodone from 0 to 8 hours after ingestion of oxycodone.

    Time frame: From 0 to 8 hours after ingestion of oxycodone

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Dec 2025, 20 months after the start.

Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
Jun 3, 2025
StartActual
Apr 12, 2024
Primary completionEst.
Dec 30, 2025
CompletionEst.
Jan 30, 2026
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07001709
Lead sponsor
Deventer Ziekenhuis
Responsible party
Sponsor
First posted
Jun 3, 2025
Start date
Apr 12, 2024
Primary completion
Dec 30, 2025 (estimated)
Completion
Jan 30, 2026 (estimated)
Last update
Jun 3, 2025

Study contacts

Frank Jansman, Prof. dr.
Contact
f.jansman@dz.nl
+31570 53 60 00
Lotte Hulskotte, drs.
Contact
l.hulskotte@dz.nl
+31631451719

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abiraterone Acetate

Start the discussion